Understanding the plant and synthetic pathways
Taking place on 27th October at 3PM London / 10AM New York, our latest webinar explores how to harness cannabinoids in drug development. We will detail the challenges associated with handling cannabinoids and will offer expert insight into how we can solve them at Recipharm.
We will discuss the following:
• The Classification of Cannabinoids – cannabinoids can be classified in several ways. They can be classed according to where they have been derived from – whether they have been purified from plants, produced by biotechnology or synthesized. In addition, they can be classified according with the affinity to different receptors in the body.
• Overview of the endogenous cannabinoid system – despite being a small family of similar compounds, cannabinoids can be used in many different and seemingly unrelated applications. We will shed light on this by exploring the array of cannabinoid receptors in the human body.
• Challenges in cannabinoid API development – developing a drug from cannabinoids presents many challenges, such as poor solubility in aqueous solution and low bioavailability.
• Synthetic vs plant-based – there is a vivid discussion in the scientific and medical community about the most effective source of raw material for cannabinoid APIs. We will explore the merits and demerits of each.
Use cases
We will explore two use cases that demonstrate effective and scalable cannabinoid development:
• Optimised plant-based development – we will discuss how an existing and widely-used extraction project can be enhanced in order to achieve a more effective scaled-up industrial method.
• Enhanced synthetic-based processes – we will explore the modifications that can be made to the development process for a synthetic cannabinoid API to ensure better yields and shorter production times.
Presented by
Sylvia G. Kachalsky, Ph.D.,
General Manager
Sylvia is General Manager at Recipharm and she is based at our Israel facility. Prior to joining Recipharm, Sylvia held many senior roles for both biotech and pharmaceutical companies. She brings a range of experience to the team and has a wealth of expertise in development, including the development of cannabinoids and cannabinoids derivatives.
Aaron Small,
Vice President Global Development Sales
Aaron holds a BSBA degree in Marketing and a MBA and has been a part of Recipharm since 2011. During his time in Recipharm he has contributed to business development activities for both development and manufacturing services. In addition Aaron has been a part of brand development and deployment for the North American market.